Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer.

Mycolactone is a polyketide macrolide lipid-like secondary metabolite synthesized by Mycobacterium ulcerans, the causative agent of BU (Buruli ulcer), and is the only virulence factor for this pathogen identified to date. Prolonged exposure to high concentrations of mycolactone is cytotoxic to diverse mammalian cells (albeit with varying efficiency), whereas at lower doses it has a spectrum of immunosuppressive activities. Combined, these pleiotropic properties have a powerful influence on local and systemic cellular function that should explain the pathophysiology of BU disease. The last decade has seen significant advances in our understanding of the molecular mechanisms underlying these effects in a range of different cell types. The present review focuses on the current state of our knowledge of mycolactone function, and its molecular and cellular targets, and seeks to identify commonalities between the different functional and cellular systems. Since mycolactone influences fundamental cellular processes (cell division, cell death and inflammation), getting to the root of how mycolactone achieves this could have a profound impact on our understanding of eukaryotic cell biology.

[1]  P. Bouchard,et al.  Mycobacterium ulcerans infections cause progressive muscle atrophy and dysfunction, and mycolactone impairs satellite cell proliferation. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.

[2]  G. Pluschke,et al.  The genome, evolution and diversity of Mycobacterium ulcerans. , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[3]  B. Foxwell,et al.  The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. , 1999, Journal of immunology.

[4]  S. Cole,et al.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans , 2009, Nature Reviews Microbiology.

[5]  E. Walker,et al.  Ecology and Transmission of Buruli Ulcer Disease: A Systematic Review , 2010, PLoS neglected tropical diseases.

[6]  Y. Kishi,et al.  Total synthesis of the mycolactones. , 2002, Organic letters.

[7]  Pierre Legras,et al.  Impact of Mycobacterium ulcerans Biofilm on Transmissibility to Ecological Niches and Buruli Ulcer Pathogenesis , 2007, PLoS pathogens.

[8]  Enrico Colombo,et al.  A Mycobacterium ulcerans toxin, mycolactone, induces apoptosis in primary human keratinocytes and in HaCaT cells. , 2010, Microbes and infection.

[9]  B. Marston,et al.  Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease. , 2000, Emerging infectious diseases.

[10]  Y. Kazumi,et al.  Synthesis and structure of two new mycolactones isolated from M. ulcerans subsp. shinshuense. , 2012, Organic Letters.

[11]  Marion Leclerc,et al.  Mycolactone Diffuses from Mycobacterium ulcerans–Infected Tissues and Targets Mononuclear Cells in Peripheral Blood and Lymphoid Organs , 2008, PLoS neglected tropical diseases.

[12]  P. Small,et al.  Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans. , 1998, Infection and immunity.

[13]  S. Rose-John,et al.  The importance of shedding of membrane proteins for cytokine biology. , 2000, European cytokine network.

[14]  J. Grosset,et al.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? , 2011, Future microbiology.

[15]  Sarojini Adusumilli,et al.  Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Pluschke,et al.  Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). , 2009, Expert opinion on biological therapy.

[17]  Sarojini Adusumilli,et al.  Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo , 2005, Cellular microbiology.

[18]  Sarojini Adusumilli,et al.  Mycolactone-Mediated Inhibition of Tumor Necrosis Factor Production by Macrophages Infected with Mycobacterium ulcerans Has Implications for the Control of Infection , 2007, Infection and Immunity.

[19]  B. Foxwell,et al.  Mycolactone Inhibits Monocyte Cytokine Production by a Posttranscriptional Mechanism1 , 2009, The Journal of Immunology.

[20]  Yoshito Kishi,et al.  Chemistry of mycolactones, the causative toxins of Buruli ulcer , 2011, Proceedings of the National Academy of Sciences.

[21]  J. Guarner,et al.  Histopathologic Features of Mycobacterium ulcerans Infection , 2003, Emerging infectious diseases.

[22]  Emmanuelle Perret,et al.  Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin , 2005, Cellular microbiology.

[23]  Hui Hong,et al.  A Novel Mycolactone from a Clinical Isolate of Mycobacterium ulcerans Provides Evidence for Additional Toxin Heterogeneity as a Result of Specific Changes in the Modular Polyketide Synthase , 2005, Chembiochem : a European journal of chemical biology.

[24]  Angelo Martino,et al.  Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone , 2007, The Journal of experimental medicine.

[25]  C. Demangel,et al.  A diverted total synthesis of mycolactone analogues: an insight into Buruli ulcer toxins. , 2011, Chemistry.

[26]  T. Grammer,et al.  A Newly Discovered Mycobacterial Pathogen Isolated from Laboratory Colonies of Xenopus Species with Lethal Infections Produces a Novel Form of Mycolactone, the Mycobacterium ulcerans Macrolide Toxin , 2005, Infection and Immunity.

[27]  W. Hockmeyer,et al.  Further characterization of Mycobacterium ulcerans toxin , 1978, Infection and immunity.

[28]  Pascal Lenormand,et al.  Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring , 2011, PLoS neglected tropical diseases.

[29]  P. Anderson Post-transcriptional control of cytokine production , 2008, Nature Immunology.

[30]  M. Goto,et al.  Mycolactone Is Responsible for the Painlessness of Mycobacterium ulcerans Infection (Buruli Ulcer) in a Murine Study , 2008, Infection and Immunity.

[31]  A. Filho,et al.  Infection with Mycobacterium ulcerans Induces Persistent Inflammatory Responses in Mice , 2005, Infection and Immunity.

[32]  Jun Li,et al.  Structure-Activity Relationship Studies on the Macrolide Exotoxin Mycolactone of Mycobacterium ulcerans , 2013, PLoS neglected tropical diseases.

[33]  S. Barik,et al.  Translation Control: A Multifaceted Regulator of Inflammatory Response , 2010, The Journal of Immunology.

[34]  C. Robinson,et al.  Microbiological, Histological, Immunological, and Toxin Response to Antibiotic Treatment in the Mouse Model of Mycobacterium ulcerans Disease , 2013, PLoS neglected tropical diseases.

[35]  A. Kemp,et al.  Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  J. Pedrosa,et al.  Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. , 2009, The Lancet. Infectious diseases.

[37]  R. Donnell,et al.  Mycobacterium ulcerans causes minimal pathogenesis and colonization in medaka (Oryzias latipes): an experimental fish model of disease transmission. , 2012, Microbes and infection.

[38]  K. Dobos,et al.  Mycobacterium ulcerans Cytotoxicity in an Adipose Cell Model , 2001, Infection and Immunity.

[39]  Georges Bismuth,et al.  Mycolactone Suppresses T Cell Responsiveness by Altering Both Early Signaling and Posttranslational Events , 2009, The Journal of Immunology.

[40]  F. Portaels,et al.  Heterogeneity of Mycolactones Produced by Clinical Isolates of Mycobacterium ulcerans: Implications for Virulence , 2003, Infection and Immunity.

[41]  J. Pedrosa,et al.  Evidence for an Intramacrophage Growth Phase of Mycobacterium ulcerans , 2006, Infection and Immunity.

[42]  W. Meyers,et al.  Immunosuppressive properties of the soluble toxin from Mycobacterium ulcerans. , 1988, The Journal of infectious diseases.

[43]  F. Portaels,et al.  Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection. , 2011, Dermatologic clinics.

[44]  Vasudevan Seshadri,et al.  Translational control by the 3'-UTR: the ends specify the means. , 2003, Trends in biochemical sciences.

[45]  P. Small,et al.  Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. , 2003, Microbial pathogenesis.

[46]  Marie-France Carlier,et al.  Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. , 2013, The Journal of clinical investigation.

[47]  P. Small,et al.  A Mycobacterium ulcerans Toxin, Mycolactone, Causes Apoptosis in Guinea Pig Ulcers and Tissue Culture Cells , 2000, Infection and Immunity.

[48]  Hui Hong,et al.  Mycolactone Gene Expression Is Controlled by Strong SigA-Like Promoters with Utility in Studies of Mycobacterium ulcerans and Buruli Ulcer , 2009, PLoS neglected tropical diseases.

[49]  J. Saklatvala,et al.  Regulation of tumour necrosis factor α mRNA stability by the mitogen‐activated protein kinase p38 signalling cascade , 2000, FEBS letters.

[50]  Matthew L Albert,et al.  Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. , 2009, The Journal of infectious diseases.

[51]  D. Connor,et al.  Mycobacterium ulcerans infection (with comments on pathogenesis). , 1965, International journal of Leprosy.

[52]  D. Chatterjee,et al.  Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. , 1999, Science.

[53]  K. Fitzgerald,et al.  Regulation of inflammasome signaling , 2012, Nature Immunology.

[54]  Georges Bismuth,et al.  Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression , 2011, Proceedings of the National Academy of Sciences.